Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

Time running out for pharma sales and marketing

February 26, 2009 Research and Development, Sales and Marketing pwC, strategy

The pharma industry's current sales and marketing model will be defunct in the next ten years. That is the stark …
News

Europe approves Lilly’s Plavix rival

February 25, 2009 Research and Development, Sales and Marketing Daiichi, Effient, lilly

Lilly and Daiichi Sankyo have won European approval for their blood-thinning drug Efient, which will go up against established blockbuster …
News

Future of new AZ asthma drug uncertain after phase III failure

February 25, 2009 Research and Development AZ, respiratory

News

NovaBiotics: a rising star for 2009

February 24, 2009 Research and Development NovaBiotics

Biologics company NovaBiotics has been dubbed a Rising Star for 2009 by the Scottish arm of the BioIndustry Association. The …
News

R&D tax credits among anticipated changes for US healthcare

February 24, 2009 Research and Development US, healthcare

With the election of Barack Obama, widespread changes are anticipated for US healthcare and ultimately for the pharmaceutical industry. Although …
News

Bringing global trials teams together

February 23, 2009 Research and Development clinical trials, global

The world is getting bigger and smaller at the same time. When the internet began to really catch on about …
Feature

Raptiva suspended in Europe over safety concerns

February 20, 2009 Research and Development, Sales and Marketing Europe, Rapitva

Psoriasis treatment Raptiva is to be suspended from use in the European Union because of concerns about rare but serious …
News

Servier claims victory over NICE in osteoporosis

February 19, 2009 Research and Development, Sales and Marketing NICE, Servier

Servier has claimed victory in the first round of its legal battle against NICE's guidelines on osteoporosis.A judicial review requested …
News

GSK’s diabetes candidate enters phase III

February 19, 2009 Research and Development GSK, diabetes

A large scale study of GlaxoSmithKline's type II diabetes candidate Syncria (albiglutide) has begun.Albiglutide is an investigational biological drug, and …
News

Genzyme says new plant approval is imminent

February 18, 2009 Research and Development, Sales and Marketing Genzyme

Genzyme has said it expects to get approval to make a Pompe disease treatment at a new US manufacturing unit …
News

Lilly to boost biotech stake in NeuroSearch deal

February 17, 2009 Research and Development Denmark, Europe, NeuroSearch

Lilly has signed a new deal with Danish biotech company NeuroSearch and increased its presence further in the biologics sector.The …
News

Pharma needs fresh ideas from outside industry, says Barker

February 17, 2009 Research and Development, Sales and Marketing ABPI, strategy

Pharma must re-invent itself and inject new ideas into its business model by hiring talented people from outside the sector, …
News

GSK: renewing the HIV pipeline

February 16, 2009 Research and Development GSK, HIV

GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK …
News

Bayer’s cardiovascular drug enters phase III

February 13, 2009 Research and Development, Sales and Marketing Bayer, cv

Bayer Schering Pharma has begun phase III trials of riociguat for treatment of two life-threatening conditions. Two trials will investigate …
News

Publish and be damned?

February 10, 2009 Research and Development clinical trials, publication

Feature
The Gateway to Local Adoption Series

Latest content

Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month

March 26, 2026

Scotland starts newborn screening for SMA

March 26, 2026

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026